By examining 4 healthcare‑associated outbreaks of SARS‑CoV‑2 infections in a German hospital, the researchers aimed to understand effective containment of SARS‑CoV‑2 in healthcare facilities.
All articles by Estie Mermelstein, MSN, FNP-BC
World Health Organization expert provided data on 4 repurposed antiviral drugs – remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a – and its use in patients hospitalized with COVID-19.
Regeneron’s antibody cocktail for COVID-19, REGN-COV2, contains 2 neutralizing antibodies: casirivimab and imdevimab; results from the phase 1/2 trial reveal promising results for patients who were antibody-negative or had high viral loads.
Investigators determined whether ABO and Rh blood groups were associated with risk for SARS-CoV-2 infection and severe COVID-19 illness.
The study authors describe the first use of valganciclovir treatment in lower-income countries for patients with CMVR, advanced HIV disease, and profound immunosuppression.
Study authors provided a systemic analysis of to identify key characteristics of extensive and advanced COVID-19.
Investigators projected changes in incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis C virus.